-
Article
Open AccessThe SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities. Currently, there are no therapies targeting this important clinical problem. Sodium-glucose cotransporter 2 inhibitors (SGLT2...
-
Article
Open AccessDiet-induced weight loss in obese/diabetic mice normalizes glucose metabolism and promotes functional recovery after stroke
Post-stroke functional recovery is severely impaired by type 2 diabetes (T2D). This is an important clinical problem since T2D is one of the most common diseases. Because weight loss-based strategies have been...
-
Article
Open AccessEstimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study
Insulin resistance contributes to the development of type 2 diabetes (T2D) and is also a cardiovascular risk factor. The aim of this study was to investigate the potential association between insulin resistanc...
-
Article
Open AccessGLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals
Glucagon-like peptide-1 (GLP-1) treatment has been shown to reduce stroke incidence in diabetes and also to be neuroprotective in experimental stroke models. The prognostic value of endogenous levels of GLP-1 ...
-
Article
Open AccessThe effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway
Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are approved drugs for the treatment of hyperglycemia in patients with type 2 diabetes. These effects are mainly mediated by inhibiting endogenous glucagon-...
-
Article
Open AccessThe high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors